BASi Offers New Cardiomonitor and Other Easy-to-Use ECG and Ventilator Products Specifically Designed for Veterinary Use

BASi's Vetronics division offers a line of in-house monitoring and diagnostic equipment that can be used easily and safely during anesthesia, post-operative recovery, and dental cleanings on animals of any size.

The new CardioMonitor from BASi is a compact device that detects ECD signals with a simple 3-lead attachment. The unit mounts on the side of a cage or rests next to the animal during surgery and is suitable for use in the field, as it runs for up to 250 continuous hours on a standard 9V battery. It provides a digital display of the animal's heart rate and has adjustable sensitivity to cover a range of species.

To monitor respiration and see real-time ECG tracings as well, BASi also offers the portable, microprocessor-controlled ERM-8010. The ERM-8010 is very sensitive, yet easy to use. Simply attach three alligator clips to the patient and connect the T-piece of the respiratory sensor with the ET tube. Instantly, the patient's heart rate, respiratory rate, and the ECG tracing will appear on the clear LCD. Effective audible and visual alarms are available for both the heart rate and apnea.

The Small Animal Ventilator, also from BASi, offers independent control of inspiratory and expiratory parameters on intubated animals from a few ounces up to 22 lbs. Ideal for exotics such as birds, lizards, iguanas and snakes, the compact unit provides a reliable method of controlling ventilation and works with any standard anesthetic machine. Status indicators on the front of the unit show clearly the valve position to indicate expiration or inspiration.

Empis Web Site

The web site for this new infusion system is at *www.empis.net.*

BASi Named One of The Hottest Small Companies

In July 2003, BASi was named to the Fortune Small Business 100 - America's Fastest-Growing Small Companies. Fortune Small Business selected public companies that trade on the major exchanges with $200 million or less in annual revenue and ranked them by earnings growth, revenue growth and stock performance over the past three years. Those rankings were averaged to create the final order for the top 100 companies.

Naturally, BASi is extremely pleased at this recognition. With the acquisition of a clinical research unit in Baltimore and LC Resources, Inc. in Oregon and several recent capital expansion projects, the company is poised for substantial continued future growth.

Award-Winning Annual Report

BASi was presented with the Gold Award by the League of American Communications Professionals in its 2002 Vision Awards annual report competition. The award was based upon excellence in such things as organization, clarity, creativity, aesthetic appeal and effectiveness. Produced entirely in house by BASi staff, this is the second year in a row BASi has been recognized for having produced an outstanding annual report.

Mark Your Calendar

The 7th International ISSX Meeting will be held in Vancouver, BC August 29 to September 2, 2004, at the Vancouver Convention & Exhibition Centre. For more information, visit *www.issx.org* or contact Nancy Holahan (*nholahan@issx.org*).

New General Manager for Clinical Trials Unit

Michael S. Noone has joined BASi as General Manager of the company's recently acquired Clinical Research Unit in Baltimore.

Mr. Noone has a rich background in the clinical trials segment of the pharmaceutical industry. He comes to BASi after being Executive Director of Neeman Medical International, a clinical trials site management organization; Senior Director of Clinical Monitoring at ClinTrials Research, Inc.; and nearly twenty years at Eli Lilly and Company in various clinical research, regulatory and cross functional roles.

With recent investments in facilities upgrades, new senior technical staff and marketing programs in place, Mike's primary challenge will be improving operating efficiency.

New Medical Director for Clinical Research Facility

Robert W. Malone, M.D. has joined BASi as Medical Director-Principal Investigator for Baltimore CRU. Dr. Malone brings us a wide variety of substantial experience, including recent concomitant roles as President and Co-Founder of Gene Delivery Alliance (a consulting and IP management firm), and Associate Director, Clinical Research, for Dynport Vaccine Company, LLC. He has also served as co-founder, CSO and Board of Directors Member for Intradigm Corporation; Associate Professor of Surgery and Chief of Laboratory Science/Director of Tissue Banking for Uniformed Services University Health Sciences-Clinical Breast Care Program; Adjunct Professor at University of South Florida-Department of Chemical Engineering; Assistant Professor at University of Maryland-Baltimore School of Medicine-Dept of Pathology, and Assistant Professor at University of California-Davis Department of Medical Pathology.

Dr. Malone has been issued 11 patents from work generated by him and his co-workers, and has submitted another five that are pending patent approval. Also, he is author of more than 30 publications and 35 abstracts, has penned two chapters for medical publications covering Gene Therapy and Toxicology of Non-viral Gene Transfer, and has served as chairperson and delivered oral presentations at 32 scientific meetings.

Dr. Malone has a Doctor of Medicine from Northwestern University Medical School, a Clinical Pathology Internship from University of California-Davis Medical Center, and has received further training as a Research Fellow and Pathology Resident in Medical Pathology, also at the University

California-Davis Medical Center. He is currently a member of the Gene Therapy/ Molecular Biology International Society, the New York Academy of Sciences, The Bioelectrochemical Society, the European Gene Therapy Society and AAAS.

Chemist Divides and Conquers for High-Throughput Analysis

Chemical-oriented industries from pharmaceuticals to petroleum are dependent on fast, efficient analysis of molecules to remain competitive. Those businesses may find their day-to-day operations easier with a technique under development in the chemistry department at Purdue University. *http://news.uns.purdue.edu/UNS/html4ever/031002.Raftery.NMR.html*

BASi Board Member W. Leigh Thompson Honored by FDA for Outstanding Contributions to Science and the Public Health

The Food and Drug Administration (FDA) has awarded Dr. W. Leigh Thompson the Commissioner's Special Citation for Profound Contributions, in Multiple Disciplines, to The Art And Science of Drug Development.

Mark B. McClellan, M.D., Ph.D., Commissioner of Food and Drug, said, "Dr. Thompson has been chosen for this award because he has provided invaluable assistance in many areas to the FDA during his distinguished career. Many of the initiatives in drug development that we are implementing today are built on the foundations he laid. His work has contributed significantly to the health of our nation."

In a career spanning nearly four decades, Dr. Thompson has made significant contributions to medical care, drug development and the public health. He has pursued collaborative drug development innovations with FDA colleagues and developed clinical trial reference ranges adopted for broad use by the agency. He consulted with the FDA on topics of drug and device development, global regulatory strategies, health informatics, strategic planning, research management, process re-engineering, and fractal portfolio resourcing.

At the Medical University of South Carolina Dr. Thompson earned a Masters Degree in Science, and a Ph.D. in 1963. His doctoral dissertation in pharmacology involved the discovery and development of hetastarch (Hespan), which became a widely used substitute for blood. Dr. Thompson earned a medical degree at The Johns Hopkins University in 1965 where he performed clinical trials and completed the New Drug Application (NDA) for hetastarch.

After completing a residency at the Johns Hopkins Osler Medical Service, Dr. Thompson then spent two years at the National Institutes of Health working as a Staff Associate at the National Cancer Institute (NCI) where he developed NCI's first critical care unit and its first electronic records of patient therapy. From 1970 to 1974 as an Assistant Professor of Medicine and of Pharmacology and Experimental Therapeutics at Johns Hopkins he developed and led the Medical Critical Care Unit, directed the Medical Emergency Department, pioneered computer-assisted instruction in pharmacokinetics and computer-based patient outcomes studies, and started the advanced practice nurse (Emergency Department Practitioner) program. He performed two-thirds of the NDA clinical trials of dopamine and was a scientific pioneer in the field of medical monitoring devices.

From 1974 to 1982 as Professor of Medicine at Case Western Reserve University, he founded and led programs in clinical pharmacology and critical care medicine (building his third ICU), directed the medical emergency department, founded and directed weekly live telecasts and videotape for continuing medical education (Medicine Today), and developed the Northeast Ohio Poison Treatment Center, Cleveland Drug Analysis Laboratory, and University Hospitals Drug Information Center.

Dr. Thompson was a medical news reporter for NBC-TV where his taped and live reports contributed to a prize-winning series. He developed novel treatments of poisoning, inventing a potent oral charcoal and a safe inhalation emetic (drug product to induce vomiting in poisoning cases). He also held grants for organizing and studying poisoning care in Northeast Ohio, for training in critical care and clinical pharmacology, and performed numerous Phase I through III clinical trials.

In 1982 Dr. Thompson joined Eli Lilly and Company as Director of Clinical Investigation of Lilly Research Laboratories and was later promoted to Executive Vice President of Lilly Research Laboratories during which time he pioneered remote data entry, direct capture of data from patients, use of a single global pivotal study in 24 countries, the first rDNA product (humulin), the first modified rDNA product (humalog), the first global electronic safety network including automated regulatory reporting, and one of the fastest NDA approvals (hGH) prior to 1990. In 1993 he was promoted to Chief Scientific Officer of Eli Lilly and Company.

In 1994 Dr. Thompson was awarded a Doctor of Medical Sciences honorary degree by the Medical University of South Carolina and was their 1999 Distinguished Alumnus. In 2003 he was elected to membership in The Johns Hopkins Society of Scholars and was the 2003 Distinguished Medical Alumnus. He is an Honorary Life Member and Past President of the Society of Critical Care Medicine and is the founder and original co-editor of *The Textbook of Critical Care and Critical Care:State of the Art*. He has authored 300 scientific papers, edited ten books, writes many monographs for about 50 major lectures a year worldwide, and is broadly acknowledged as one of the best public speakers in medicine.

After his retirement from Eli Lilly in 1995, Thompson was CEO of Profound Quality Resources, Ltd., where he consulted worldwide with academic health centers and with manufacturers of drugs, devices and diagnostics. He was an initial member of the Council for International Organizations of Medical Science (CIOMS) program in global adverse event reporting and in the International Conference on Harmonization (ICH) of regulatory requirements. His pioneering initiatives in critical care, pharmaceutical development innovations, information technology management and collaborations with regulators has been remarkable and left a sustaining positive impact on the industry, patients and the many professionals whom he has mentored.

Dr. Thompson is a member of BASi's Scientific Advisory Committee and has served as a Director of the corporation since 1997. He and his wife, Maurice, recently authored an entertaining mystery novel, *Murder At Spoleto*.